Up to week 16 , the most common adverse events were upper respiratory tract infections ( four [ 4 % ] , eight [ 8 % ] , ten [ 10 % ] , and seven [ 7 % ] with secukinumab 300 mg , 150 mg , 75 mg , and placebo , respectively ) and nasopharyngitis ( six [ 6 % ] , four [ 4 % ] , six [ 6 % ] , and eight [ 8 % ] , respectively ) .